Patent applications published 23 February 2011

Published: 4-Apr-2011

Selected patent applications from the weekly European Patents Bulletin


  • Improved quenching methods for red blood cell pathogen inactivation
    Cerus 2285210*

  • Novel pyriproxyfen compsns
    Valent 2285212*

  • Microemulsion germicidal compsn
    Ethicon 2285213*

  • Rasagiline soft gelatin capsules
    Teva Pharmaceutical Industries 2285214*

  • Novel compounds, pharmaceutical compsns containing same, and methods for use of same
    Fasgen, The Johns Hopkins University 2285215*

  • HIV protease inhibitor and cytochrome P450 inhibitor combinations
    Sequoia Pharmaceuticals 2285216*

  • Compounds for improving learning and memory
    Amnestix 2285217*

  • Dietary compsns and methods for protection against chemotherapy, radiotherapy, oxidative stress and ageing
    University of Southern California 2285218*

  • Controlled release formulations of alprazolam
    Supernus Pharmaceuticals 2285219*

  • Sweet containing algae for the prevention of oro-dental infections
    Roquette Freres 2285344*

  • Pulmonary delivery of a fluoroquinolone
    Novartis 2285345*

  • Methods for improving lid margin and tear film function and treatment of lid margin disease using tetracycline family antibiotics
    Donnenfled, Eric 2285346*

  • Compsns and methods for treating digestive disorders
    Revalesio 2285347*

  • Opioid compsn for treating skin lesions
    Euro-Celtique 2285348*

  • Perfluorocarbon nanoemulsions with endocytosis enhancing surface for gene-transfer
    Soluventis 2285349*

  • Methods for the preparation of targeting agent functionalised diblock copolymers for use in fabrication of therapeutic targeted nanoparticles
    Bind Biosciences 2285350*

  • Oral pharmaceutical compsns in a solid dispersion comprising preferably posaconazole and HPMCAS
    Schering 2285351*

  • Atrovastatin compsns
    Dr Reddy’s Laboratories Ltd; Dr Reddy’s Laboratories Inc 2285352*

  • Modified release formulations of HMG CoA reductase inhibitors
    Lupin 2285353*

  • Process for preparing a low drug load tablet
    Atacama Labs 2285354*

  • Process for preparing a high drug load tablet
    Atacama Labs 2285355*

  • Process for preparing a tablet comprising metformin
    Atacama Labs 2285356*

  • Pharmaceutical compsns comprising brivaracetam
    UCB Pharma 2285357*

  • Pulsatile release of valsartan
    Novartis 2285358*

  • Solid pharmaceutical formulation with delayed release
    Bayer Animal Health 2285359*

  • Medicament delivery device having an electronic circuit system
    Intelliject 2285360*

  • Therapeutic calcium phosphate particles and methods of making and using same
    Nod Pharmaceuticals 2285361*

  • Compsn for transdermal delivery of cationic active agents
    LTS Lohmann Therapie-Systeme 2285362*

  • Alpha adrenergic receptor agonists for treatment of inflammatory diseases
    Warsaw Orthopaedic; Medtronic 2285363*

  • Therapeutic replenishment and enrichment of ocular surface lubrication
    The Regents of the University of California; Schepens Eye Research Institute 2285364*

  • Use of a compsn comprising at least one beta-blocker for the treatment of sleep disorders
    Tullin, Soren; Oslen, Birger Jan 2285365*

  • Molecules inhibiting a metabolic pathway involving the SYK protein tyrosine kinase and method for identifying said molecules
    Centre National de la Recherche Scientifique 2285366*

  • Pharmaceutical compsn for the treatment of warts
    ATP Marketing & Promotion 2285367*

  • New use
    Syntopix Group 2285368*

  • Sulphobetaines for cancer, obesity, macular degeneration, neurodegenerative diseases
    Titian Pharma 2285369*

  • Use of a combination of udenafil and alfuzosin or oxybutynon for the treatment of overactive bladder
    Plevipharm 2285370*

  • Pharmaceutical formulations and methods of use which combine non-steroidal anti-inflammatory compounds with anti-hypertensive compounds
    Hoyle, Peter 2285371*

  • Selective subtype alpha 2 adrenergic agents and methods for use thereof
    Allergan 2285372*

  • Treatment of organophosphate exposure with tetrahydroindolone arylpiperazine compounds
    Cenomed Biosciences 2285373*

  • Combination compsns for treating Alzheimer’s disease and related disorders with zonisamide and acamprosate
    Pharnext 2285374*

  • Spirazaindoles
    Merck Sharp & Dohme 2285375*

  • 6-aminonicotinamide derivatives as potent and selective histone deacetylase inhibitors
    Chipscreen Biosciences 2285376*

  • Method for treating cognitive deficits
    H Lundbeck 2285377*

  • Treatment for ocular-related disorders
    Sanofi-Aventis 2285378*

  • 1-methylnicotinamide analogues
    Cortia 2285379*

  • Methods for using TGF-B receptor inhibitors or activin-like kinase (ALK) 5 inhibitors A-83-01 and SB-431542 to treat eye disease and wound healing conditions
    Summa Health Systems 2285380*

  • Photoactivatable antimicrobial agents and therapeutic and diagnostic methods of using same
    The General Hospital Corp 2285381*

  • Steroidal compounds as melanogenesis modifiers and uses thereof
    New York University 2285382*

You may also like